Place · Level 3 · Supplement
α-Lipoic acid (ALA)
线粒体辅基不是营养素 · 糖尿病周围神经病变 IV 用药真证据 · 减脂营销 -0.65 kg 真相 · R-ALA 商业溢价拆穿
Story path
Chapter 1
Dual-soluble
Dual-soluble
α-lipoic acid (ALA / thioctic acid) is an 8-carbon fatty acid containing a disulfide (-S-S-) ring, first isolated in 1951 by Reed's lab.
What's special about the chemical structure:
8-carbon fatty acid backbone → lipid-solubleDisulfide bond + carboxyl group → water-solubleDual water/lipid solubility, quite rare among vitamins + antioxidantsVit C is water-only, vit E / A lipid-only, GSH water-only — most antioxidants work in one phase onlyALA can enter cytosol, membranes, mitochondria, and nucleus simultaneously
Two stereoisomers (chirality):
R-ALA (dextrorotatory): the naturally occurring form, also what the body synthesizes and usesS-ALA (levorotatory): a synthetic byproduct, weak biological activityCommercial ALA is usually racemic (50% R + 50% S) — low industrial-synthesis costR-ALA-only products advertise 'natural form', but oral R-ALA has poor stability (polymerizes); only salt forms like R-ALA-Na are actually stable
Endogenous synthesis:
ALA is synthesized inside mitochondria from octanoic acid + sulfur supplyNot an essential nutrient (unlike vitamins, which must come from food)But synthesis may decline under aging / pathology, so supplementation has some theoretical rationale
Food content:
Red meat (organ): 5–30 µg/100 gSpinach / broccoli: ~5 µg/100 gYeast / tomato: traceFood content is extremely low — reaching supplemental doses (300–600 mg) from food is impossible
Key fact: 'ALA is an essential nutrient' is supplement-marketing misdirection. It's not a vitamin and not a 'deficiency-causes-disease' molecule — it's an endogenous metabolic cofactor + an optional therapeutic drug (IV in diabetic neuropathy).
What's special about the chemical structure:
8-carbon fatty acid backbone → lipid-solubleDisulfide bond + carboxyl group → water-solubleDual water/lipid solubility, quite rare among vitamins + antioxidantsVit C is water-only, vit E / A lipid-only, GSH water-only — most antioxidants work in one phase onlyALA can enter cytosol, membranes, mitochondria, and nucleus simultaneously
Two stereoisomers (chirality):
R-ALA (dextrorotatory): the naturally occurring form, also what the body synthesizes and usesS-ALA (levorotatory): a synthetic byproduct, weak biological activityCommercial ALA is usually racemic (50% R + 50% S) — low industrial-synthesis costR-ALA-only products advertise 'natural form', but oral R-ALA has poor stability (polymerizes); only salt forms like R-ALA-Na are actually stable
Endogenous synthesis:
ALA is synthesized inside mitochondria from octanoic acid + sulfur supplyNot an essential nutrient (unlike vitamins, which must come from food)But synthesis may decline under aging / pathology, so supplementation has some theoretical rationale
Food content:
Red meat (organ): 5–30 µg/100 gSpinach / broccoli: ~5 µg/100 gYeast / tomato: traceFood content is extremely low — reaching supplemental doses (300–600 mg) from food is impossible
Key fact: 'ALA is an essential nutrient' is supplement-marketing misdirection. It's not a vitamin and not a 'deficiency-causes-disease' molecule — it's an endogenous metabolic cofactor + an optional therapeutic drug (IV in diabetic neuropathy).
R-ALA premium debunked
'R-ALA is the natural form, S-ALA is useless, you must buy pure R-ALA' — the supplement-marketing 'chirality premium' line. Let's go through the evidence point by point.First, R-ALA really is the natural + biologically active form:
Mitochondrial ALA is the R formPDH / KGDH cofactor is the R formS-ALA basically cannot enter the active sites of mitochondrial enzymes
Second, but after oral dosing the two forms diverge:
Oral R-ALA is unstable in gastric acid, polymerizes easily and partially degradesOral S-ALA has better chemical stability but weak biological activityRacemic ALA (50% R + 50% S) is industrially synthesized, with moderate stabilityR-ALA-Na (sodium salt) / R-LA stable forms solve the stability problem but cost 5–10× racemic
Third, PK studies (Carlson 2007 *Altern Med Rev*):
Racemic 300 mg → plasma R-ALA peak 4–5 µM, S-ALA peak 6–8 µMR-ALA-Na 100 mg → plasma R-ALA peak 8–10 µMEfficiency difference: R-ALA-Na is 2–3× more efficient per mg, but whether clinical endpoint improvement matches that gap is weakly supported
Fourth, the ALADIN series RCTs used racemic:
All A-level evidence (diabetic neuropathy) used racemic ALA, not R-ALAR-ALA-only clinical evidence is sparse, mostly PK + small metabolic-marker studies'R-ALA is clinically stronger' is not an evidence-based conclusion — it's a marketing extrapolation
In practice:
If you're certain you want ALA + budget tight: racemic 300–600 mg, $10–20/month, fully reasonableIf you're willing to pay the premium + want theoretical optimum: R-ALA-Na 100–300 mg, $40–80/month'Only buy R-ALA, never racemic' marketing isn't science — the A-level ALADIN evidence used racemic
Bottom line: the chirality premium is a mix of real commercial + PK data + heavy marketing extrapolation. The rational supplementation is to follow the ALADIN protocol with racemic; if you self-experiment with R-ALA-Na, recognize you're paying for theoretical advantage, not RCT evidence.
Chapter 2
Mitochondrial cofactor
Mitochondrial cofactor
ALA's 'day job' in the body is not antioxidant — it's mitochondrial enzyme cofactor. This is the fact most often skipped in marketing.
Key roles:
Pyruvate dehydrogenase (PDH): ALA is covalently bound to the E2 subunit, the key cofactor for pyruvate → acetyl-CoA (TPP/B1 is also a cofactor on the same enzyme; see the thiamin/tpp L4)α-ketoglutarate dehydrogenase (KGDH): key step in the TCA cycleBranched-chain α-keto acid dehydrogenase (BCKD): leucine / isoleucine / valine metabolismGlycine cleavage system: Gly + THF → 5,10-MTHF + CO₂ + NH₃, part of the SHMT pathway mentioned in the Atlas glycine story
So ALA is a central cofactor for glucose metabolism + tricarboxylic acid (Krebs) cycle: The mitochondrial hub cycle that fully oxidizes fuel and harvests electrons for energy. + BCAA + one-carbon metabolism — involving the body's most important metabolic lines.
The 'antioxidant' role is secondary and marketing-amplified:
Dihydrolipoic acid (DHLA) = the reduced form of ALAThe thiol (-SH) on DHLA does clear ROS and chelate heavy metalsBut DHLA is the post-reduction form in vivo; endogenous DHLA concentration is low (because most endogenous ALA is locked into cofactor roles)After oral ALA, the body reduces it to DHLA via GR / thioredoxin reductase, giving a brief antioxidant boostHalf-life ~30 minutes — an acute effect, not sustained
The 'ALA as network-antioxidant hub' framing (Packer 1995):
DHLA can recycle the oxidized forms of vit C, vit E, GSH, CoQ10This is the core of the 'antioxidant network' theory: ALA isn't a point antioxidant but a network hubThe mechanism is real, but clinical endpoint validation is weak (the vit-e/membrane L4 already covered the 'perfect mechanism → failed RCT' lesson; ALA antioxidant RCTs follow the same pattern)
Bottom line:
ALA's primary role is cofactor; with adequate endogenous synthesis no supplementation is neededThe antioxidant function is a side job, briefly present during high-dose supplementation'ALA antioxidant → systemic anti-aging' is another version of the vit E + antioxidant mega-pack marketingIf ALA could really deliver broad-spectrum anti-aging, RCTs would have shown it — but there's no large-trial hard-endpoint RCT evidence for lifespan / CVD / cancerIts real value lies in specific clinical indications, not 'wellness'
Key roles:
Pyruvate dehydrogenase (PDH): ALA is covalently bound to the E2 subunit, the key cofactor for pyruvate → acetyl-CoA (TPP/B1 is also a cofactor on the same enzyme; see the thiamin/tpp L4)α-ketoglutarate dehydrogenase (KGDH): key step in the TCA cycleBranched-chain α-keto acid dehydrogenase (BCKD): leucine / isoleucine / valine metabolismGlycine cleavage system: Gly + THF → 5,10-MTHF + CO₂ + NH₃, part of the SHMT pathway mentioned in the Atlas glycine story
So ALA is a central cofactor for glucose metabolism + tricarboxylic acid (Krebs) cycle: The mitochondrial hub cycle that fully oxidizes fuel and harvests electrons for energy. + BCAA + one-carbon metabolism — involving the body's most important metabolic lines.
The 'antioxidant' role is secondary and marketing-amplified:
Dihydrolipoic acid (DHLA) = the reduced form of ALAThe thiol (-SH) on DHLA does clear ROS and chelate heavy metalsBut DHLA is the post-reduction form in vivo; endogenous DHLA concentration is low (because most endogenous ALA is locked into cofactor roles)After oral ALA, the body reduces it to DHLA via GR / thioredoxin reductase, giving a brief antioxidant boostHalf-life ~30 minutes — an acute effect, not sustained
The 'ALA as network-antioxidant hub' framing (Packer 1995):
DHLA can recycle the oxidized forms of vit C, vit E, GSH, CoQ10This is the core of the 'antioxidant network' theory: ALA isn't a point antioxidant but a network hubThe mechanism is real, but clinical endpoint validation is weak (the vit-e/membrane L4 already covered the 'perfect mechanism → failed RCT' lesson; ALA antioxidant RCTs follow the same pattern)
Bottom line:
ALA's primary role is cofactor; with adequate endogenous synthesis no supplementation is neededThe antioxidant function is a side job, briefly present during high-dose supplementation'ALA antioxidant → systemic anti-aging' is another version of the vit E + antioxidant mega-pack marketingIf ALA could really deliver broad-spectrum anti-aging, RCTs would have shown it — but there's no large-trial hard-endpoint RCT evidence for lifespan / CVD / cancerIts real value lies in specific clinical indications, not 'wellness'
Cooperation with thiamin TPP
ALA and thiamin (B1) are the classic example of 'two cofactors on one enzyme' inside mitochondria.The PDH enzyme complex:
PDH is a huge multi-subunit complex (~9 MDa, 60–90 protein units)Three core subunits:E1 (PDH-α/β): uses TPP (thiamin) as cofactor, breaks the C-C bond of pyruvateE2 (dihydrolipoamide acetyltransferase): uses lipoamide (covalently bound ALA) as cofactor, accepts the acetyl groupE3 (dihydrolipoyl dehydrogenase): uses FAD (riboflavin / B2) + nicotinamide adenine dinucleotide: A coenzyme that ferries electrons to drive energy production — built from vitamin B3. (B3) as cofactors, regenerates the oxidized lipoamide
Reaction chain:
```
pyruvate ─→ [E1·TPP] ─→ hydroxyethyl-TPP
↓
[E2·lipoamide] ─→ acetyl-lipoamide ─→ acetyl-CoA (output)
↓ (dihydrolipoamide)
[E3·FAD] ─→ lipoamide (oxidized, recycled) + NADH (energy output)
```
So a single PDH reaction needs 5 cofactors present simultaneously:
TPP (B1) — thiaminlipoamide (ALA) — α-lipoic acidFAD (B2) — riboflavinNAD⁺ (B3) — niacinCoA (B5) — pantothenic acid
This is a quiet convergence of 5 Atlas B-vitamin stories: thiamin/tpp L4, riboflavin/flavins L4, niacin/nad L4, and the pantothenic-acid story all meet at this single enzyme. Any one of them being short slows PDH, jams pyruvate at the end of glycolysis, and piles up lactate.
KGDH (α-ketoglutarate dehydrogenase) has the same cofactor lineup:
At the α-KG → succinyl-CoA step in the tricarboxylic acid (Krebs) cycle: The mitochondrial hub cycle that fully oxidizes fuel and harvests electrons for energy. cycleNeeds TPP + lipoamide + FAD + NAD⁺ + CoA equally
Mechanism takeaway:
'Supplementing ALA boosts energy metabolism' is reasonable when ALA is severely deficient (rare)Modern healthy adults have sufficient endogenous ALA, and this 'cofactor topping-up' hypothesis has almost no RCT support clinicallyIf you really want to support energy metabolism, the priority is: a foundation of food + B1 + B2 + B3 + CoA from diet, vastly outperforming ALA supplementation
This is a concrete sample of how the Atlas uses the 'cofactor cooperation diagram' to explain 'why single supplements often don't work': energy metabolism isn't 'missing X, supplement X' — it's the entire factory running in sync.
Chapter 3
Diabetic neuropathy A-grade
Diabetic neuropathy A-grade
ALA's real A-level clinical evidence is diabetic peripheral neuropathy (DPN) — a prescription drug in Germany / several European countries for 50 years, still a supplement in the US.
The ALADIN series RCTs (1995–2006):
**ALADIN I (Ziegler 1995 *Diabetologia*, n=328)**: IV ALA 600 mg/day × 3 weeks, symptom score (TSS) improved significantly vs placeboALADIN II (Reljanovic 1999, n=65): long-term IV + oral sequential, nerve conduction improvedALADIN III (Ziegler 1999, n=509): IV 600 mg × 3 wk + oral 1800 mg/day × 6 months, sustained improvement**SYDNEY-2 (Ziegler 2006 *Diabetes Care*, n=181)**: oral 600 / 1200 / 1800 mg/day × 5 weeks, dose response, 600 mg/day best value
Ziegler 2006 meta (4 RCTs, n=1,258 pooled):
IV ALA 600 mg/day × 3 wk → TSS (Total Symptom Score) dropped 50% vs placebo 30%Treatment responders (≥ 50% improvement): ~50% in ALA arm vs ~25% in placeboNNT (number needed to treat) ≈ 4, clinically significant
Mechanism (hypothesis):
DPN pathology: hyperglycemia → polyol pathway + protein glycation + oxidative stress → axonal injuryALA → DHLA → clears ROS in nerve tissue + raises GSH + improves nerve microvascular flowDirect antioxidant + improved neural endothelial perfusion
Clinical status (2025):
Germany / Austria / central Europe: ALA (brand Thioctacid) is a prescription drug, approved in 1966, used for DPN for 50+ yearsUS: still OTC supplement, but ADA 2024 guidelines list ALA as 'non-conventional therapy worth considering'China: ALA (thioctic acid injection) is a prescription drug for diabetic neuropathy
What ALA cannot do:
Reverse already-dead neurons — ALA cannot regenerate neuronsSubstitute for glycemic control — glucose control remains the foundation of DPN treatmentPrevent DPN — no primary-prevention evidence
In practice:
Diagnosed DPN + good glycemic control but persistent symptoms: discuss IV ALA 600 mg/day × 3 weeks, or oral 600 mg/day long-term, with endocrinology / neurologyDiabetes + early sensory abnormalities: glycemic control + ADA first-line (pregabalin / duloxetine) is preferred over ALA, but ALA is a reasonable adjunctNon-diabetic neuropathy (chemo / B12 deficiency / alcohol): ALA evidence is weak, not first-line
The ALADIN series RCTs (1995–2006):
**ALADIN I (Ziegler 1995 *Diabetologia*, n=328)**: IV ALA 600 mg/day × 3 weeks, symptom score (TSS) improved significantly vs placeboALADIN II (Reljanovic 1999, n=65): long-term IV + oral sequential, nerve conduction improvedALADIN III (Ziegler 1999, n=509): IV 600 mg × 3 wk + oral 1800 mg/day × 6 months, sustained improvement**SYDNEY-2 (Ziegler 2006 *Diabetes Care*, n=181)**: oral 600 / 1200 / 1800 mg/day × 5 weeks, dose response, 600 mg/day best value
Ziegler 2006 meta (4 RCTs, n=1,258 pooled):
IV ALA 600 mg/day × 3 wk → TSS (Total Symptom Score) dropped 50% vs placebo 30%Treatment responders (≥ 50% improvement): ~50% in ALA arm vs ~25% in placeboNNT (number needed to treat) ≈ 4, clinically significant
Mechanism (hypothesis):
DPN pathology: hyperglycemia → polyol pathway + protein glycation + oxidative stress → axonal injuryALA → DHLA → clears ROS in nerve tissue + raises GSH + improves nerve microvascular flowDirect antioxidant + improved neural endothelial perfusion
Clinical status (2025):
Germany / Austria / central Europe: ALA (brand Thioctacid) is a prescription drug, approved in 1966, used for DPN for 50+ yearsUS: still OTC supplement, but ADA 2024 guidelines list ALA as 'non-conventional therapy worth considering'China: ALA (thioctic acid injection) is a prescription drug for diabetic neuropathy
What ALA cannot do:
Reverse already-dead neurons — ALA cannot regenerate neuronsSubstitute for glycemic control — glucose control remains the foundation of DPN treatmentPrevent DPN — no primary-prevention evidence
In practice:
Diagnosed DPN + good glycemic control but persistent symptoms: discuss IV ALA 600 mg/day × 3 weeks, or oral 600 mg/day long-term, with endocrinology / neurologyDiabetes + early sensory abnormalities: glycemic control + ADA first-line (pregabalin / duloxetine) is preferred over ALA, but ALA is a reasonable adjunctNon-diabetic neuropathy (chemo / B12 deficiency / alcohol): ALA evidence is weak, not first-line
Why FDA didn't approve
ALA is a prescription drug in Europe for 50 years yet still a supplement in the US — a regulatory-divergence story.The German path:
1966: ALA (brand Thioctacid) was approved by German BfArM for DPN, based on early IV studies + clinical experience1989–2006: the ALADIN series + SYDNEY series RCTs further solidified the evidenceIt remains a routinely used drug in German neurology + diabetology to this day
The US FDA path:
The FDA never formally approved ALA as a drugReasons are complex:No pharma company ever submitted a complete NDA (New Drug Application)ALA's 1955 patent had long expired — no commercial incentiveThe US neuropathy treatment market is dominated by pregabalin (Lyrica, Pfizer) and duloxetine (Cymbalta, Lilly), making it hard for a new generic to break inResult: ALA remains a supplement in the US, and manufacturers cannot claim 'treats diabetic neuropathy'
This tells us:
'Not FDA-approved' ≠ 'ineffective' — regulatory approval is a product of commercial + political + clinical-evidence interplayThe same molecule can be 'drug vs supplement' in different countries, mostly driven by patent / commercial incentive / regulatory preferenceUS off-label prescribing: some physicians do prescribe ALA for diabetic neuropathy, but insurance usually doesn't cover it — patients pay out-of-pocket for supplement-grade ALA
Other similar molecules:
L-carnitine: prescription drug in Europe (heart failure + neuropathy), supplement in the USCoenzyme Q10: prescription drug in Japan (heart failure), supplement in US/EUNAC: FDA prescription drug in US (acetaminophen antidote) + OTC supplement, mostly prescription in Europe5-MTHF (active folate Metafolin): GRAS food ingredient in US, prescription raw material in Europe
In practice:
When evaluating supplements, look at specific evidence grade + indication, not just 'is it FDA-approved''50-year German prescription' + 4 ALADIN RCTs + Ziegler meta is stronger evidence than most US OTC supplementsBut ALA is a DPN drug, not a 'wellness' supplement — the Atlas emphasizes this repeatedly
Chapter 4
Weight loss myth
Weight loss myth
'ALA the fat-loss miracle' is another loud track in ALA marketing — but the actual data is sobering.
Mechanistic basis (hypothesis):
ALA → activates AMP-activated protein kinase: The cell's 'low fuel' sensor — switches on when energy is low to make energy and pause building. → suppresses lipogenesis + promotes fat oxidation (true in animal models)ALA → improves insulin sensitivity, indirectly aiding fat lossALA → suppresses hypothalamic AMPK → reduces appetite (Kim 2004 *Nat Med* mouse study)These mechanisms placed ALA in the 'fat loss + anti-metabolic-syndrome' market narrative
Actual human RCTs (Kucukgoncu 2017 *Obesity Reviews* systematic review + meta):
12 RCTs, n=534 participants (most with metabolic syndrome / diabetes / obesity background)300–1800 mg/day × 8–24 weeksWeighted mean effect: weight −1.27 kg (95% CI −2.29 to −0.25)BMI −0.43 kg/m²Waist circumference: weak signal, not significant
Najafi 2022 meta update:
Similar result: weight −0.65 to −1.5 kg, poor clinical significanceSmall effect + high heterogeneity, with most trials including concurrent diet + exercise
Translated:
'ALA loses 0.65–1.5 kg' is over 8–24 weeks — averaging only 0.1–0.3 kg per monthClinical significance threshold is usually ≥ 5% of starting weight: a 70 kg person needs to lose 3.5 kg — ALA falls far shortCompared with Ozempic (semaglutide): 17–20% weight loss over 68 weeks, 1–2 kg per monthCompared with a plain 500 kcal/day deficit: 0.4–0.5 kg per week, 3–4 kg over 8 weeks
So:
ALA's fat-loss effect is real but negligible in magnitudeIt cannot replace diet + exercise + glucagon-like peptide-1: A gut hormone released after eating that makes you feel full and helps lower blood sugar.-class drugs when meaningful loss is needed'ALA is a weight-loss drug' marketing is a textbook case of a small mechanistic signal being inflated into a clinical hook
Atlas overall: ALA's fat-loss position mirrors its 'anti-aging' position — mechanism plausible, small signal exists, clinical significance weak, marketing far exceeds evidence. If you're prediabetic + insulin-resistant + already doing the diet / exercise basics, ALA is a reasonable marginal trial; if you want ALA to substitute for lifestyle or expect significant weight loss, this road doesn't go there.
Mechanistic basis (hypothesis):
ALA → activates AMP-activated protein kinase: The cell's 'low fuel' sensor — switches on when energy is low to make energy and pause building. → suppresses lipogenesis + promotes fat oxidation (true in animal models)ALA → improves insulin sensitivity, indirectly aiding fat lossALA → suppresses hypothalamic AMPK → reduces appetite (Kim 2004 *Nat Med* mouse study)These mechanisms placed ALA in the 'fat loss + anti-metabolic-syndrome' market narrative
Actual human RCTs (Kucukgoncu 2017 *Obesity Reviews* systematic review + meta):
12 RCTs, n=534 participants (most with metabolic syndrome / diabetes / obesity background)300–1800 mg/day × 8–24 weeksWeighted mean effect: weight −1.27 kg (95% CI −2.29 to −0.25)BMI −0.43 kg/m²Waist circumference: weak signal, not significant
Najafi 2022 meta update:
Similar result: weight −0.65 to −1.5 kg, poor clinical significanceSmall effect + high heterogeneity, with most trials including concurrent diet + exercise
Translated:
'ALA loses 0.65–1.5 kg' is over 8–24 weeks — averaging only 0.1–0.3 kg per monthClinical significance threshold is usually ≥ 5% of starting weight: a 70 kg person needs to lose 3.5 kg — ALA falls far shortCompared with Ozempic (semaglutide): 17–20% weight loss over 68 weeks, 1–2 kg per monthCompared with a plain 500 kcal/day deficit: 0.4–0.5 kg per week, 3–4 kg over 8 weeks
So:
ALA's fat-loss effect is real but negligible in magnitudeIt cannot replace diet + exercise + glucagon-like peptide-1: A gut hormone released after eating that makes you feel full and helps lower blood sugar.-class drugs when meaningful loss is needed'ALA is a weight-loss drug' marketing is a textbook case of a small mechanistic signal being inflated into a clinical hook
Atlas overall: ALA's fat-loss position mirrors its 'anti-aging' position — mechanism plausible, small signal exists, clinical significance weak, marketing far exceeds evidence. If you're prediabetic + insulin-resistant + already doing the diet / exercise basics, ALA is a reasonable marginal trial; if you want ALA to substitute for lifestyle or expect significant weight loss, this road doesn't go there.
Real position in MetS
ALA's real position in the metabolic syndrome (MetS) + insulin resistance (IR) spectrum.Meaningful signals:
Fasting insulin / HOMA-IR: ALA 300–600 mg/day × 8–24 weeks, HOMA-IR improves 10–20%Fasting glucose: weak signal, not significantHbA1c: weak signal, not significantTriglycerides / LDL: small improvement in some studiesInflammation marker (C-reactive protein: A liver protein that rises with inflammation — a common blood marker for 'is the body inflamed'.): small decrease in some studies
Meaning:
ALA has a 'real but small' effect across the IR spectrum, mostly on early insulin-sensitivity markersCannot replace:Weight loss (first-line for MetS)Metformin (first-line for type 2 diabetes)GLP-1 (newer effective, semaglutide / tirzepatide)Diet (low GI / Mediterranean / DASH)Exercise (resistance + aerobic)
Atlas priority order (MetS / IR intervention):
1. Diet improvement + 5–10% weight loss (A-level hard endpoint, DiRECT trial)
2. Exercise (150 min/week moderate aerobic + 2× resistance, A-level)
3. Metformin (prediabetes → type 2, A-level)
4. glucagon-like peptide-1: A gut hormone released after eating that makes you feel full and helps lower blood sugar. class (semaglutide, A-level obesity + DM breakthrough)
5. Berberine (B-level, see berberine story)
6. NAC + vit D + magnesium (B–C level, depending on baseline)
7. ALA 300–600 mg/day (B–C level, marginal trial after #1–5 are dialed in)
8. TMG + creatine + protein (baseline nutrition, not directly targeting MetS)
9. Other (D-level)
In practice:
Metabolic syndrome / IR / prediabetes: #1–3 are core, ALA ranks #7Diagnosed type 2 diabetes + peripheral neuropathy: ALA suddenly becomes A-level (that's the DPN indication)Healthy people who want 'metabolic syndrome protection': no need for ALA — spend the money on diet + exercise + sleep + weight
Bottom line: ALA is a typical supplement-aisle sample of 'clear mechanism + specific clinical niche + extremely broad marketing', in the same tier as NAC / curcumin. Within its precise indications (DPN, part of MetS) it is genuinely effective, but 'anti-aging / fat loss / antioxidant miracle' marketing far exceeds the evidence.
Chapter 5
Decision tree
Decision tree
Do you need to take ALA?
Strongly recommended scenarios (A-level evidence):
1. Diagnosed diabetic peripheral neuropathy (DPN) + persistent symptoms: discuss IV 600 mg/day × 3 weeks, or long-term oral 600 mg/day, with endocrinology / neurology
2. Diabetes + early sensory abnormalities (DPN risk) + glycemic control + medications + still progressing: ALA as adjunct (first-line is still pregabalin / duloxetine)
Worth considering scenarios (B–C evidence):
3. Metabolic syndrome / IR / prediabetes + diet + exercise + weight management already in place + want a marginal add-on: 300–600 mg/day × 8–24 weeks, watching HOMA-IR / weight changes
4. Chemotherapy-induced peripheral neuropathy: evidence weak, but some oncology services will trial it
5. Non-alcoholic fatty liver disease (NAFLD) + metabolic syndrome: small RCT signal, discuss with hepatology / nutrition
Lower priority / not recommended (D-level):
Healthy people taking ALA long-term for 'anti-aging' / 'antioxidant': no hard-endpoint evidence — food + training + sleep have higher ROI'Miracle fat loss': 0.65–1.5 kg over 24 weeks, clinically insignificantPreventing diabetes / DPN: no primary-prevention evidenceNon-diabetic neuropathy (B12 / alcohol / autoimmune): find the cause and treat it; ALA is not a substitute
Dosing protocols:
DPN acute loading: IV 600 mg/day × 3 weeksDPN maintenance: oral 600 mg/day long-termMetabolic syndrome / IR: 300–600 mg/day'Wellness' / general antioxidant: no fixed dose recommended, no supporting evidence
Form choices:
Racemic ALA (50% R + 50% S): cheapest, ~$10–20/month — what the ALADIN series usedR-ALA-Na (sodium salt): more expensive, $40–80/month — better PK, but weak evidence for clinical-endpoint equivalenceR-ALA free acid: unstable, not recommendedCombo metabolic-support multi-ingredient blends: unclear dosing, marketing premium
Safety + side effects:
GI discomfort: 5–10% (at high doses)Rash / allergy: rareInsulin sensitization → hypoglycemia risk: diabetics on glucose-lowering meds must monitor blood glucose and reduce meds as neededThyroid: high-dose ALA may affect T3/T4 — caution in Hashimoto's + Graves' patientsOverdose (> 10 g acute): seizure + death cases reported
Atlas overall: ALA is a typical paradox-molecule in the supplement aisle — a true clinical drug + extensive marketing. Inside the DPN indication it's a real drug; outside the 'anti-aging / weight loss' framing it's marketing. The evaluation point isn't ALA itself — it's that your specific situation determines whether it works for you.
Strongly recommended scenarios (A-level evidence):
1. Diagnosed diabetic peripheral neuropathy (DPN) + persistent symptoms: discuss IV 600 mg/day × 3 weeks, or long-term oral 600 mg/day, with endocrinology / neurology
2. Diabetes + early sensory abnormalities (DPN risk) + glycemic control + medications + still progressing: ALA as adjunct (first-line is still pregabalin / duloxetine)
Worth considering scenarios (B–C evidence):
3. Metabolic syndrome / IR / prediabetes + diet + exercise + weight management already in place + want a marginal add-on: 300–600 mg/day × 8–24 weeks, watching HOMA-IR / weight changes
4. Chemotherapy-induced peripheral neuropathy: evidence weak, but some oncology services will trial it
5. Non-alcoholic fatty liver disease (NAFLD) + metabolic syndrome: small RCT signal, discuss with hepatology / nutrition
Lower priority / not recommended (D-level):
Healthy people taking ALA long-term for 'anti-aging' / 'antioxidant': no hard-endpoint evidence — food + training + sleep have higher ROI'Miracle fat loss': 0.65–1.5 kg over 24 weeks, clinically insignificantPreventing diabetes / DPN: no primary-prevention evidenceNon-diabetic neuropathy (B12 / alcohol / autoimmune): find the cause and treat it; ALA is not a substitute
Dosing protocols:
DPN acute loading: IV 600 mg/day × 3 weeksDPN maintenance: oral 600 mg/day long-termMetabolic syndrome / IR: 300–600 mg/day'Wellness' / general antioxidant: no fixed dose recommended, no supporting evidence
Form choices:
Racemic ALA (50% R + 50% S): cheapest, ~$10–20/month — what the ALADIN series usedR-ALA-Na (sodium salt): more expensive, $40–80/month — better PK, but weak evidence for clinical-endpoint equivalenceR-ALA free acid: unstable, not recommendedCombo metabolic-support multi-ingredient blends: unclear dosing, marketing premium
Safety + side effects:
GI discomfort: 5–10% (at high doses)Rash / allergy: rareInsulin sensitization → hypoglycemia risk: diabetics on glucose-lowering meds must monitor blood glucose and reduce meds as neededThyroid: high-dose ALA may affect T3/T4 — caution in Hashimoto's + Graves' patientsOverdose (> 10 g acute): seizure + death cases reported
Atlas overall: ALA is a typical paradox-molecule in the supplement aisle — a true clinical drug + extensive marketing. Inside the DPN indication it's a real drug; outside the 'anti-aging / weight loss' framing it's marketing. The evaluation point isn't ALA itself — it's that your specific situation determines whether it works for you.
ALA position in Atlas G4
ALA's position in the Atlas Supplements continent.| Dimension | ALA | NAC | Curcumin | Fish oil | Vit D |
|---|---|---|---|---|---|
| Mechanism clarity | A (cofactor + antioxidant) | A | A | A | A |
| Clinical indication | DPN A-level | paracetamol A | OA mid-high-dose B | EPA/DHA B-A | deficiency A |
| Marginal indication | MetS B / IR C | COPD B / OCD B | anti-inflammation B / depression C | general CVD B-C | general population C |
| Over-marketing | weight loss + anti-aging | anti-COVID | universal anti-inflammatory | heart miracle | prevents everything |
| Real cost | $10–20 (racemic) | $10–15 | $15–30 (poor absorption) | $10–30 | $5–10 |
Shared pattern:
Clear mechanism + specific clinical indication + broad marketingEffective within the true indication, D-level + marketing outside it'Evaluating a supplement = evaluating molecule × person × state' — the Atlas's recurring framework
ALA's position:
Diabetic neuropathy patients: A-level clinical evidence, stronger than the vast majority of supplementsMetabolic syndrome + poor glucose control: B-level adjunct, ranked after diet / exercise / drugsHealthy people wanting anti-aging / fat loss: D-level, not a priority
In the same tier as other 'supplement-grade drugs' with clear indications:
NAC: paracetamol A, COPD B–A, OCD BCurcumin: OA + chronic inflammation B, anti-cancer / anti-aging Domega-3 (EPA + DHA): high triglycerides + selected CVD B–A, general prevention B–CALA: DPN A, MetS B, anti-aging / fat loss D
What unites this group: clear mechanism + strong RCT in a narrow indication + marketing trying to extend it to a broader audience.
Reader's tool: when you see any 'X cures everything' marketing, drop X into this table — the default pattern is 'A in narrow indication, D in broad marketing'.